Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma

Fineline Cube May 21, 2026
Company Drug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

Fineline Cube Jan 3, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...

Company Drug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...

Company Drug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

Fineline Cube Jan 3, 2025

US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...

Company Drug

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

Fineline Cube Jan 3, 2025

China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

Shanghai Enacts New Regulations for Drug and Medical Device Administration

Fineline Cube Jan 3, 2025

The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...

Company Drug

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Fineline Cube Jan 3, 2025

Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...

Company Deals

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

Fineline Cube Jan 3, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...

Company Drug

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

Fineline Cube Jan 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...

Company Drug

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Fineline Cube Jan 3, 2025

Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...

Company Drug

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Medical Device

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment

Fineline Cube Jan 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...

Company Drug

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

Fineline Cube Jan 3, 2025

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial

Fineline Cube Jan 3, 2025

Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...

Company Deals

Cygenta Partners with IZVARINO Pharma for Comprehensive CDMO Services

Fineline Cube Jan 3, 2025

Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based...

Company Deals

Pfizer Collaborates with Atavistik Bio to Discover Allosteric Therapeutics

Fineline Cube Jan 3, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm...

Company Drug

NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...

Company Medical Device

Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery

Fineline Cube Jan 2, 2025

Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from...

Company Drug

Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management

Fineline Cube Jan 2, 2025

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...

Company Deals

Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing

Fineline Cube Jan 2, 2025

Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...

Company Deals

Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines

Fineline Cube Jan 2, 2025

China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property...

Posts pagination

1 … 238 239 240 … 669

Recent updates

  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Company Medical Device

Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.